Use of the cytokine IP-10 as an anti-tumor agent

Details Use of the cytokine IP-10 as an anti-tumor agent Use of the cytokine IP-10 as an anti-tumor agent

1999-06-04

2000-11-28

Hauda, Karen M.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

4353201, 435375, 536 235, 536 2352, A01N 4304, A61K 3170, C07H 2104, C12N 1500, C12N 1509, C12N 506, C12N 516

Patent

active

061536008

ABSTRACT:
Methods and therapeutic compositions for inhibiting neoplasms by administration of a nucleic acid sequence encoding the IP-10 polypeptide.

REFERENCES:
patent: 5098702 (1992-03-01), Zimmerman et al.
patent: 5179078 (1993-01-01), Rollins et al.
patent: 5236829 (1993-08-01), Farber
patent: 5248666 (1993-09-01), Twardzik et al.
Narvariza et al., "Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma.-inducible protein 0 10 and another encoding IL-12, results in marked antitumoral synergy.", Journal of Immunology, vol. 164 (6): 3112-3122, 2000.
Jain, K R., "Vascular and interstitial barriers to delivery of therapeutic agents in tumors". Cancer and Metastasis Review 9: pp. 253-266, 1990.
Orkin et al., "Report and recommendations of the panel to assess the NIH investment in research on gene therapy". pp. 1-20, Dec. 1995.
Sidransky D., "Nucleic acid-based methods for the detection of cancer". Science; vol. 278 pp. 1054-1058, Nov. 1997.
Verma et al., "Gene therapy-promises, problems, and prospects". Nature; vol. 389 pp. 239-242, Sep. 1997.
Anderson W F, "Human gene therapy". Nature; vol. 392 Supp pp. 25-30, Apr. 1998.
Baggiolini et al, J. Clin. Invest. 84:1045-1049 (1989).
Friedmann, Cancer (Supp) 70(6):1810-1818 (1992).
Gottlieb et al., J. Exp. Med. 168:941-948 (1988).
Gutierrez et al., The Lancet 339:715-721 (1992).
Kaplan et al., J. Exp. Med. 168:1811-1824 (1988).
Kaplan et al., J. Exp. Med. 166:1098-1108 (1987).
Luster et al., Nature 315:672-676 (1985).
Luster et al., PNAS 84:2868-2871 (1987).
Luster et al., J. Exp. Med. 166:1084-1097 (1987).
Luster et al., Proc Natl. Acad. Sci. USA 84:2868-2871 (1987).
Luster et al., J. Exp. Med. 178:1057-1065 (1993).
Luster and Ravetch, Molecular and Cellular Biology 7:3723-3731 (1987).
Matsushima et al., J. Exp. Med. 169:1485-1490 (1989).
Maione et al., Science 247:77-79 (1990).
Narumi et al., J. Leu. Biology 52:27-33 (1992).
Narumi et al., J. of Immunology 146:3038-3044 (1991).
Richmond and Thomas, J. Cell. Physiology 129:375-384 (1986).
Rollins and Sunday, Molecular and Cellular Biology 11:3125-3131 (1991).
Tepper et al., Cell 57:503-512 (1989).
Vanguri et al., J. Biol. Chem. 265:15049-15057 (1990).
Wolpe and Cerami, FASEB J. 3:2565-2573 (1989).
Wu Pong, Pharmaceutical Tech. 18:102-114 (1994).
Report and Recommendations fo the Panel to Assess the NIH Investment in Research on Gene Therapy Dec. 7, 1995.

Affiliated with

Also associated with

Rating

Use of the cytokine IP-10 as an anti-tumor agent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of the cytokine IP-10 as an anti-tumor agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of the cytokine IP-10 as an anti-tumor agent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1725983